

Product datasheet for **TL301681V**

SLAMF7 Human shRNA Lentiviral Particle (Locus ID 57823)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	SLAMF7 Human shRNA Lentiviral Particle (Locus ID 57823)
Locus ID:	57823
Synonyms:	19A; CD319; CRACC; CS1
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	SLAMF7 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_001282588 , NM_001282589 , NM_001282590 , NM_001282591 , NM_001282592 , NM_001282593 , NM_001282594 , NM_001282595 , NM_001282596 , NM_021181 , NM_021181.1 , NM_021181.2 , NM_021181.3 , NM_021181.4 , NM_001282593.1 , NM_001282588.1 , NM_001282591.1 , NM_001282596.1 , NM_001282595.1 , NM_001282589.1 , NM_001282590.1 , NM_001282594.1 , NM_001282592.1 , BC027867 , NM_001282590.2 , NM_001282596.2 , NM_001282592.2 , NM_021181.5
UniProt ID:	Q9NQ25
Summary:	Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Isoform 1 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway (PubMed:11698418). Positively regulates NK cell functions by a mechanism dependent on phosphorylated SH2D1B. Downstream signaling implicates PLCG1, PLCG2 and PI3K (PubMed:16339536). In addition to heterotypic NK cells-target cells interactions also homotypic interactions between NK cells may contribute to activation. However, in the absence of SH2D1B, inhibits NK cell function. Acts also inhibitory in T-cells (By similarity). May play a role in lymphocyte adhesion (PubMed:11802771). In LPS-activated monocytes negatively regulates production of proinflammatory cytokines (PubMed:23695528).[UniProtKB/Swiss-Prot Function]



[View online »](#)

shRNA Design:

These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our [custom shRNA service](#).

Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).